Selank

Mechanism

Evidence tier: 4 — Receptor pharmacology and downstream BDNF/GABA effects characterized in Russian preclinical work; human mechanism inferred rather than directly measured in Western RCT.

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is a stabilized analog of the immune-active fragment Tuftsin (residues 289-292 of the IgG heavy chain), with a C-terminal Pro-Gly-Pro tripeptide added to extend plasma half-life from minutes to hours. The intended indication is generalized anxiety disorder.

The proposed mechanism operates on three putative axes. First, Selank upregulates expression of brain-derived neurotrophic factor (BDNF) in the hippocampus of stressed rodents, an effect that may underlie its anxiolytic and procognitive signals. Second, it modulates GABA-ergic neurotransmission indirectly, with mouse-model work showing enhanced GABA-A receptor function without direct receptor binding — a profile that could explain the absence of sedation and dependence seen with benzodiazepine anxiolytics. Third, Selank shifts the cytokine balance toward a Th1 profile and modulates enkephalin metabolism, which the Russian literature has linked to its antidepressant-like effects.

The mechanistic case for Selank is preclinical in nature. There is no human PET, fMRI, or microdialysis data confirming any of these effects in vivo at clinically used doses. The Russian RCTs that established Selank's anxiolytic profile measured clinical outcomes (Hamilton Anxiety Scale) rather than mechanism. Treat the mechanism as a working hypothesis rather than established science.

Typical protocols

Evidence tier: 2 — Doses are RCT-derived from the Russian trials; western protocols largely follow those schedules.

Selank is administered intranasally as a 0.15% saline solution. Per the Zozulia 2008 (PMID 18454096) protocol, the trial dose was 900 mcg per day (typically 300 mcg three times daily, or 2 drops in each nostril three times daily) for 14 days. The Volkova 2018 (PMID 30255741) protocol used similar dose ranges in a generalized anxiety + neurasthenia population.

Community-circulated protocols outside the Russian formulary commonly extend treatment to 21-30 days, with some users reporting cycled use rather than continuous dosing. Single-dose effects on subjective anxiety appear within 30-60 minutes per the Russian psychometric data, with the cumulative anxiolytic effect building over the first week. Because the molecule is administered intranasally, dose precision depends heavily on spray-device calibration — compounded preparations from research suppliers vary widely.

Evidence by indication

Evidence tier: 2 — Russian RCTs in GAD with psychometric primary endpoints. No Western RCT replication exists as of 2026.

Generalized anxiety disorder: Zozulia 2008 (PMID 18454096) is the canonical Russian RCT comparing Selank to medazepam (a benzodiazepine) in GAD patients. The trial reported broadly equivalent anxiolytic efficacy on the Hamilton Anxiety Scale, with Selank showing a superior side-effect profile (no sedation, no cognitive slowing, no withdrawal phenomena) and an additional procognitive signal on attention tasks.

GAD with neurasthenia: Volkova 2018 (PMID 30255741) replicated the anxiolytic profile in a broader anxiety-spectrum population, with concurrent improvement on quality-of-life and asthenic-symptom scales over a 14-day treatment course.

Adjunctive use in psychiatric comorbidity: Several Russian observational studies and case series describe Selank as an adjunct in alcohol-withdrawal anxiety, post-stroke anxiety, and depressive disorders. These are not RCTs and the methodology is heterogeneous.

Cognition: Several preclinical studies in rodents show working-memory and attention improvements that the Russian group has attributed to BDNF upregulation. Human cognition data is limited to the procognitive secondary endpoints in the Zozulia trial.

The fundamental limitation is the absence of Western RCT replication. Selank has not been studied in a Phase 2 or Phase 3 program by any FDA- or EMA-regulated sponsor. The published Russian trials use psychometric primary endpoints that are inherently subjective, and the trials are smaller (n=60-90 typical) than what FDA registration would require. The mechanism-of-action literature is largely from a single Russian research group.

Safety profile

Evidence tier: 2 — Adverse-event reporting from the Russian RCTs is consistent across studies; long-term human safety data is sparse.

Documented adverse events in the Russian trials are mild and infrequent. The most commonly reported include nasal irritation from the intranasal vehicle, mild headache in the first 1-3 days, and occasional drowsiness (less than with benzodiazepine comparators). No clinically significant changes in routine hematology, hepatic function, or cardiovascular parameters have been reported across the published trial program.

Importantly, Selank does not show the dependence, tolerance, or withdrawal signal that limits long-term benzodiazepine use — the Russian literature places this as the molecule's primary clinical advantage. Contraindications are not well-characterized: pregnancy and lactation use is not supported by trial data, and pediatric use is undocumented in any Western language.

Theoretical concerns include immune modulation (given the Tuftsin parent), drug-drug interactions with other CNS-active agents, and the unknowns of long-term BDNF modulation. None of these have produced documented adverse events but none have been formally studied in long-term pharmacovigilance.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning across the anxiolytic landscape.

For generalized anxiety, the validated treatment hierarchy in 2026 is SSRIs/SNRIs (first-line, RCT-grade efficacy, well-characterized AE profile), buspirone (non-sedating, no dependence), and benzodiazepines (rapid-onset, dependence-limiting). Selank's hypothetical place would be as a non-dependence-forming, rapid-onset anxiolytic — but the absence of Western RCT data places it firmly in the research-context category rather than the validated-treatment category.

Within the Russian-origin peptide nootropic class, Selank shares the intranasal delivery and mechanism-of-action positioning with Semax, the related ACTH(4-10) analog developed by the same research group. Semax is more procognitive/dopaminergic; Selank is more anxiolytic/GABA-ergic. The pair is sometimes used together as the "Selank-Semax stack" in nootropic communities — see the Semax-vs-Adderall comparison for the dopaminergic positioning.

A related porcine-brain-derived neuropeptide preparation with substantially more clinical data is Cerebrolysin, though Cerebrolysin's primary indications are stroke and dementia rather than GAD.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

Selank is not FDA-approved for any indication, not on the FDA bulks list for 503A or 503B compounding, and is not lawfully available through US compounding pharmacy channels. It is approved and marketed in Russia and several CIS countries as an anxiolytic, with corresponding regulatory dossiers held by the Russian Ministry of Health rather than EMA or FDA. WADA does not currently list Selank. US-based access is via research-supplier channels only, with the standard purity, contamination, and dose-accuracy concerns that apply to all unregulated peptide supply. Patients considering Selank for anxiety should discuss validated SSRI/SNRI alternatives with a clinician before pursuing research-supplier material.

References

• Zozulia AA, Neznamov GG, Siuniakov TS, et al. 2008. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. PMID 18454096
• Volkova AL, Voronova IV, Sarsania KS. 2018. Anxiolytic peptide selank in the treatment of generalized anxiety disorder. Zh Nevrol Psikhiatr Im S S Korsakova. PMID 30255741
• Kosfeld M, Heinrichs M, Zak PJ, et al. 2005. Oxytocin increases trust in humans. Nature. PMID 15931222 — cited only as comparator for intranasal peptide CNS-delivery precedent.

Limitations

This page does not constitute medical advice. Patients with active suicidal ideation, severe depression, or psychotic-spectrum illness should not pursue Selank as a substitute for evidence-based psychiatric care. The Russian trial program, while methodologically reasonable for its era, has not been replicated by Western groups, and the absence of independent confirmation is a meaningful limitation that distinguishes Selank from the FDA-approved anxiolytics. We would change our framing if a Western Phase 2 or Phase 3 trial were initiated and read out — until then, the molecule sits in a research-context category that warrants clinician-supervised consideration rather than self-experimentation.